TB-500

TB-500 is a synthetic peptide fragment of thymosin beta-4 (TB4), a naturally occurring 43-amino-acid protein found in nearly every human cell. While TB-500 and thymosin beta-4 are often used interchangeably in biohacking circles, they are not the same molecule — TB-500 is a specific fragment designed to capture the active region of the full-length protein. It has become one of the most popular research peptides for tissue repair and recovery, frequently paired with BPC-157 in the so-called "Wolverine Stack."

The appeal is understandable. TB-500's parent protein, thymosin beta-4, plays a documented role in cell migration, wound healing, and anti-inflammatory signaling. The research on the full-length protein is more robust than what exists for the fragment alone. But the critical distinction — that TB-500 is a fragment product sold as a research chemical, not the full clinically studied protein — often gets lost in the marketing noise.

This guide covers what TB-500 actually is, how it differs from thymosin beta-4, what the animal data shows, where the evidence stops, and what vendor quality data reveals about the products being sold.

What Is TB-500?

TB-500 is a synthetic peptide corresponding to the active region of thymosin beta-4. The specific sequence that defines TB-500 centers on the actin-binding domain of thymosin beta-4, particularly the region around amino acids 17-23 (the sequence LKKTETQ), which has been identified as the primary segment responsible for TB4's cell migration and wound healing properties.

[CITATION: PubMed study needed on identification of thymosin beta-4 active region and LKKTETQ sequence]

Thymosin beta-4 itself was first isolated from the thymus gland in the 1960s and has since been found to be one of the most abundant intracellular proteins in eukaryotic cells. Its primary intracellular function is regulating actin polymerization — the process by which cells build their internal skeleton and generate the mechanical forces needed for movement, division, and shape change.

The key distinction between TB-500 and thymosin beta-4 is molecular. Thymosin beta-4 is the full 43-amino-acid protein. TB-500 is a shorter synthetic fragment. While the fragment contains what researchers believe to be the most biologically active portion of the molecule, it is not identical to the full protein, and assuming identical biological activity between the two is scientifically unjustified without direct comparative data.

For a detailed analysis of the full-length protein, including its human clinical data in ophthalmology, see our thymosin beta-4 profile.

How TB-500 Works: Mechanism of Action

Actin Regulation and Cell Migration

The core mechanism of TB-500 derives from thymosin beta-4's role as a major actin-sequestering protein. Actin is a structural protein that forms the cytoskeleton of cells, and its polymerization (assembly into filaments) and depolymerization (disassembly) is essential for cell migration, wound healing, and tissue repair.

By binding to monomeric actin (G-actin), thymosin beta-4 maintains a pool of unpolymerized actin available for rapid deployment when cells need to move — such as during wound healing, when cells at the wound edge need to migrate into the damaged area. TB-500 is believed to replicate this actin-regulatory function through its conserved active domain.

[CITATION: PubMed study needed on thymosin beta-4 actin sequestration and cell migration mechanism]

Anti-Inflammatory Effects

TB-500 and thymosin beta-4 have demonstrated anti-inflammatory properties in animal models. The mechanism appears to involve downregulation of pro-inflammatory cytokines and modulation of the NF-kB pathway, one of the central regulatory pathways for inflammatory gene expression.

[CITATION: PubMed study needed on thymosin beta-4 anti-inflammatory mechanisms and NF-kB modulation]

In models of cardiac injury, corneal damage, and skin wounds, the anti-inflammatory effects appear to create a more favorable environment for tissue repair — reducing destructive inflammation while preserving the constructive inflammatory signals needed for healing.

Angiogenesis

Like BPC-157, TB-500 has demonstrated pro-angiogenic properties, promoting the formation of new blood vessels. This effect is mediated through different pathways than BPC-157's VEGF-centric mechanism, but the net result is similar — improved blood supply to damaged tissues. And the same theoretical cancer concern applies: any compound that promotes new blood vessel formation could theoretically support tumor growth.

[CITATION: PubMed study needed on thymosin beta-4 angiogenic properties]

Hair Follicle Stem Cell Activation

An interesting secondary finding from thymosin beta-4 research is its ability to activate hair follicle stem cells, promoting new hair growth in animal models. This finding has generated interest in TB-500 for hair loss applications, though the evidence remains preclinical.

[CITATION: PubMed study needed on thymosin beta-4 hair follicle stem cell activation]

What the Animal Research Shows

Cardiac Repair

Some of the most compelling thymosin beta-4 animal data comes from cardiac research. In mouse models of myocardial infarction (heart attack), thymosin beta-4 treatment reduced scar size, improved cardiac function, and promoted the formation of new blood vessels in the damaged heart tissue. These studies used the full-length thymosin beta-4 protein, not the TB-500 fragment.

[CITATION: PubMed study needed on thymosin beta-4 cardiac repair in mouse myocardial infarction models]

Wound Healing

Thymosin beta-4 has demonstrated wound healing acceleration in multiple animal models, including full-thickness skin wounds, corneal injuries, and burn injuries. The mechanism involves enhanced keratinocyte and endothelial cell migration, collagen deposition, and angiogenesis. Again, most of this data uses the full-length protein.

[CITATION: PubMed study needed on thymosin beta-4 wound healing acceleration in animal models]

Tendon and Musculoskeletal Repair

Animal studies have shown that thymosin beta-4 can improve tendon repair outcomes, reduce adhesion formation after tendon surgery, and accelerate functional recovery from muscle injuries. The cell migration mechanism is particularly relevant here, as tendon healing requires the organized migration of tenocytes (tendon cells) into the damaged area.

[CITATION: PubMed study needed on thymosin beta-4 tendon repair in animal models]

Neurological Effects

Thymosin beta-4 has shown neuroprotective effects in animal models of traumatic brain injury and stroke, with improvements in neurological function scores and reductions in brain lesion size. The mechanisms include promotion of oligodendrocyte progenitor cell differentiation and angiogenesis in the peri-infarct region.

[CITATION: PubMed study needed on thymosin beta-4 neuroprotection in TBI and stroke models]

The Equine and Veterinary Connection

TB-500 has an interesting history in veterinary medicine, particularly in horse racing, that provides additional context for understanding its biological effects and regulatory trajectory.

Thymosin beta-4 gained notoriety in the horse racing industry in the 2000s and 2010s when it was reportedly used to enhance recovery and performance in racehorses. Several racing jurisdictions subsequently banned the substance, and positive tests for thymosin beta-4 in racehorses led to sanctions and disqualifications.

[CITATION: PubMed or regulatory reference needed on thymosin beta-4 use and regulation in equine sports]

The veterinary context is relevant for several reasons:

1. Practical evidence of biological activity: The widespread use in racehorses, where performance outcomes are closely measured, provides indirect evidence that the compound has measurable biological effects — even if this evidence doesn't meet clinical trial standards.
2. Regulatory precedent: The banning of thymosin beta-4 in animal sports preceded and influenced its prohibition by WADA for human athletes.
3. Dose-response observations: Veterinary use, while not controlled research, generated practical observations about dosing ranges, timing, and effects that inform (but do not replace) the lack of formal human pharmacokinetic data.

Evidence Limitations

Fragment vs. Full-Length Protein

The most fundamental limitation of the TB-500 evidence base is that most published research uses full-length thymosin beta-4, not the TB-500 fragment. While TB-500 contains the identified active region of the protein, fragments do not always replicate the activity of their parent molecules. Protein folding, post-translational modifications, and interactions between different domains of the full-length protein can all influence biological activity in ways that a fragment may not capture.

To understand the full protein and its more established evidence base, see our thymosin beta-4 profile.

Limited Independent Replication

Like BPC-157, the thymosin beta-4 research base is concentrated among a relatively small number of research groups. While the diversity of research teams is somewhat better than for BPC-157, independent replication remains limited for many of the specific claims made about TB-500.

No Human Trials for TB-500 Specifically

While thymosin beta-4 (the full protein) has some human clinical data — particularly in ophthalmology, where it has been studied for corneal healing — TB-500 specifically has not been studied in human clinical trials. The safety and efficacy data from thymosin beta-4 human studies cannot be automatically applied to the TB-500 fragment, because fragment pharmacology can differ from full-protein pharmacology in unpredictable ways.

The Translation Problem

Even setting aside the fragment-vs-protein issue, the translation of animal tissue repair data to human clinical outcomes has a poor historical track record. Many compounds that accelerate wound healing or tissue repair in rodent models fail to replicate those effects in human trials. Rodent tissue repair is inherently faster and more robust than human tissue repair, and the inflammatory and immune environments differ significantly between species.

Risks and Side Effects

Reported Side Effects (Anecdotal)

Without human clinical trial data for TB-500, side effect information comes from anecdotal reports:

• Headache, particularly in the first few days of use
• Lethargy and fatigue
• Nausea
• Injection site reactions (pain, redness, irritation)
• Temporary sensation of head rush or lightheadedness
• Flu-like symptoms during initial doses

Theoretical Risks

• Cancer promotion: Like BPC-157, TB-500's pro-angiogenic and cell-migration-promoting properties theoretically could support tumor growth or metastasis. No long-term data exists to evaluate this risk.
• Immune modulation: Given thymosin beta-4's origin in the thymus gland (a key immune organ), there are theoretical concerns about immune system effects with chronic use, though these have not been systematically studied.
• Unknown long-term effects: No data exists on the consequences of repeated TB-500 use over months or years.

[CITATION: PubMed study needed on thymosin beta-4 long-term safety considerations]

Drug Interactions

Potential interactions based on mechanism of action include:

• Immunosuppressive drugs: TB-500's immune-modulating properties could interact with immunosuppressants
• Anti-cancer therapies: Particularly anti-angiogenic agents
• Anticoagulants: Cell migration and angiogenesis effects could theoretically influence clotting dynamics
• Corticosteroids: Both compounds affect inflammatory pathways, with uncertain combined effects

Dosing: What Research Has Examined

Animal studies of thymosin beta-4 have used varying doses depending on the model and route of administration. The most common dosing protocols reported in clinical and biohacking communities for TB-500 include:

• Loading phase: 2-5 mg administered twice weekly via subcutaneous injection for 4-6 weeks
• Maintenance phase: 2-5 mg administered once weekly or biweekly
• Typical cycle duration: 8-12 weeks total, followed by a washout period

These protocols are derived from anecdotal practice, not clinical research. The optimal dose, frequency, and duration for any application in humans remain undetermined. Research has examined both systemic subcutaneous injection and localized injection near injury sites, with the systemic route being more commonly recommended due to TB-500's proposed systemic cell migration effects.

The Wolverine Stack: TB-500 + BPC-157

The combination of TB-500 with BPC-157 has become one of the most popular peptide protocols in the biohacking community. The name "Wolverine Stack" references the fictional X-Men character's regenerative abilities, and the marketing around this combination leans heavily into that imagery.

The theoretical rationale has some mechanistic logic:

• BPC-157 primarily promotes angiogenesis, growth factor modulation, and nitric oxide system regulation
• TB-500 primarily promotes cell migration, actin regulation, and anti-inflammatory signaling
• Together, they theoretically address different aspects of the tissue repair cascade

However, there is zero published research — animal or human — studying this specific combination. The synergistic effects are purely hypothetical, and the safety of combining two pro-angiogenic compounds with complementary growth-promoting mechanisms has never been evaluated. The theoretical cancer risk from each compound individually would presumably be at least additive, if not synergistic, when combined.

Vendor Quality Data

Market Overview

The TB-500 vendor landscape includes approximately 38 vendors with 180 tested samples providing quality data.

Quality Findings

Third-party testing of TB-500 products reveals similar patterns to the broader research peptide market:

• Purity: Ranges from approximately 95% to 99%+ HPLC purity across vendors
• Quantity accuracy: Significant variance exists, with some vendors delivering substantially less peptide than labeled
• Identity verification: Mass spectrometry testing is critical for TB-500, as the fragment nature of the product makes substitution or truncation more likely than with simpler peptides

Sourcing Considerations

When evaluating TB-500 vendors, the same principles apply as for any research peptide: look for published COAs with HPLC purity data and mass spectrometry identity confirmation, prefer vendors with multiple independently verified test results, and be skeptical of pricing significantly below market average. See our vendor scoring methodology for detailed evaluation criteria.

Legal Status

TB-500's legal status mirrors that of most research peptides:

• Not FDA-approved for any human use
• Not a controlled substance under US law
• Legal to purchase as a research chemical in most jurisdictions
• Prohibited by WADA for competitive athletes
• Not eligible for pharmacy compounding under recent FDA guidance

As with all research peptides, international regulations vary. Some countries classify peptides differently, and import restrictions may apply.

Who Should Consider TB-500

Individuals who might reasonably consider TB-500 are those who:

• Have chronic musculoskeletal injuries or slow-healing wounds that have not responded to conventional treatment
• Understand the difference between TB-500 (fragment) and thymosin beta-4 (full protein) and accept the additional uncertainty
• Have no history of cancer or immunological conditions
• Are not taking immunosuppressive medications or anti-cancer therapies
• Are working with a physician who can monitor for adverse effects
• Are sourcing from a vendor with verified third-party testing

Who Should Avoid TB-500

• Anyone with current or prior cancer diagnosis
• Individuals with autoimmune conditions or compromised immune function
• Pregnant or nursing women
• Competitive athletes subject to WADA testing
• Anyone taking immunosuppressive or anti-cancer medications
• Individuals unwilling to accept the uncertainty of using a research chemical without human safety data

TB-500 in Context: Comparing Regenerative Peptides

Understanding where TB-500 fits relative to other regenerative peptides helps frame realistic expectations:

• vs. BPC-157: BPC-157 works primarily through VEGF-driven angiogenesis and growth factor modulation. TB-500 works primarily through actin regulation and cell migration. BPC-157 has a larger published research base (200+ studies vs. a smaller number for TB-500/TB4). Both lack human clinical trials for the specific compounds sold as research chemicals.
• vs. Thymosin Beta-4: TB-500 is a fragment of thymosin beta-4. The full protein has human clinical trial data (primarily ophthalmology). TB-500 does not. If evidence quality matters to you, thymosin beta-4 is the better-supported option — but it's harder to source and more expensive.
• vs. GHK-Cu: GHK-Cu has actual human trial data for skin and wound healing applications. For topical anti-aging and wound healing, GHK-Cu has a stronger evidence base. For musculoskeletal and cardiac repair, TB-500/TB4 has more relevant animal data.
• vs. KPV: KPV is primarily anti-inflammatory with a gut focus, while TB-500 is primarily regenerative with a musculoskeletal focus. Different applications with different mechanisms.

For detailed peptide comparisons, see our comparison tools and peptide category pages.

Frequently Asked Questions